Sanofi Japan to Sharpen Focus on Priority Pipelines as It Eyes Turnaround after 2022: President

Sanofi Japan President Takahiko Iwaya The Japan arm of Sanofi is aiming for a turnaround in 2022 or soon after, hoping that a narrowed focus on six key pipeline compounds and its top-seller Dupixent (dupilumab) will help it climb out...read more